Economic analysis of the use of recombinant human granulocyte colony stimulating factor in autologous bone marrow transplantation
- 30 June 1996
- journal article
- research article
- Published by Elsevier in European Journal Of Cancer
- Vol. 32 (7) , 1162-1165
- https://doi.org/10.1016/0959-8049(95)00655-9
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Effect of Lenograstim on the Cost of Autologous Bone Marrow TransplantationPharmacoEconomics, 1995
- Cost-effectiveness comparisons using “real world” randomized trials: The case of new antidepressant drugsJournal of Clinical Epidemiology, 1995
- G‐ and GM‐CSF in oncology and oncological haematologyEuropean Journal of Haematology, 1994
- Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapyAnnals of Oncology, 1994
- Placebo-controlled phase III trial of lenograstim in bone-marrow transplantationThe Lancet, 1994
- Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropeniaThe Pediatric Infectious Disease Journal, 1994
- Recombinant Granulocyte-Macrophage Colony-Stimulating Factor after Autologous Bone Marrow Transplantation for Lymphoid CancerNew England Journal of Medicine, 1991
- Economic Analysis Alongside Clinical Trials: Revisiting the Methodological IssuesInternational Journal of Technology Assessment in Health Care, 1991
- GRANULOCYTE COLONY-STIMULATING FACTOR AND NEUTROPHIL RECOVERY AFTER HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE MARROW TRANSPLANTATIONThe Lancet, 1989
- ACCELERATION OF NEUTROPHILIC GRANULOCYTE RECOVERY AFTER BONE-MARROW TRANSPLANTATION BY ADMINISTRATION OF RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTORThe Lancet, 1988